Baudax Bio (NASDAQ:BXRX) and Caladrius Biosciences (NASDAQ:CLBS) Critical Survey

Baudax Bio (NASDAQ:BXRX) and Caladrius Biosciences (NASDAQ:CLBS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Institutional and Insider Ownership

8.1% of Caladrius Biosciences shares are held by institutional investors. 8.6% of Caladrius Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Baudax Bio and Caladrius Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Baudax Bio N/A N/A N/A
Caladrius Biosciences N/A -56.79% -46.69%

Valuation and Earnings

This table compares Baudax Bio and Caladrius Biosciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Baudax Bio N/A N/A N/A N/A N/A
Caladrius Biosciences $35.28 million 0.75 -$16.17 million ($1.67) -1.53

Baudax Bio has higher earnings, but lower revenue than Caladrius Biosciences.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Baudax Bio and Caladrius Biosciences, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baudax Bio 0 0 2 0 3.00
Caladrius Biosciences 0 1 3 0 2.75

Baudax Bio presently has a consensus price target of $12.00, suggesting a potential upside of 106.19%. Caladrius Biosciences has a consensus price target of $10.42, suggesting a potential upside of 308.50%. Given Caladrius Biosciences’ higher probable upside, analysts clearly believe Caladrius Biosciences is more favorable than Baudax Bio.

Summary

Caladrius Biosciences beats Baudax Bio on 5 of the 8 factors compared between the two stocks.

Baudax Bio Company Profile

There is no company description available for Baudax Bio Inc.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Receive News & Ratings for Baudax Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baudax Bio and related companies with MarketBeat.com's FREE daily email newsletter.